Abstract:Abstract Background and Aims Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and some glucagon-like-1 receptor agonists (GLP1-RA) have demonstrated to delay diabetic nephropathy (DN) progression. Potentially, the combination of these two therapeutic approaches on top of the standard of care with renin angiotensin system (RAS) blockers could exert additive cardiorenal protection in the diabetic milieu. The present study aimed to evaluate the cardiorenal protective effects of the combination of SGLT2i and GLP1-RA on top of RAS blockade versus the monotherapies on top of RAS blockade in experimental diabetes. Method Twelve weeks old male and female uninefrectomized (UNx) db/db mice were treated for 8 weeks with an SGLT2i (empagliflozin, 10 mg/Kg/day five days a week) and/or a GLP1-RA (semaglutide, 10.0 nmol/kg twice per week) on top of a RAS blocker (ramipril, 8 mg/Kg/day). Vehicle-treated UNx db/db and non-diabetic (db/m) mice were included as controls. During the experiment weight, food and water intake, blood glucose, blood pressure (BP) and glomerular filtration rate (GFR) were measured. Kidney and heart were collected at the end of the experiment. Results The vehicle-treated UNx db/db showed increased body weight, food and water intake and blood glucose as compared to the vehicle-treated UNx db/m (Fig. 1A, B and C, p = 0.03, p<0.001 and p<0.0001, respectively). The GFR slope (ΔGFR, difference between final and basal GFR) was also significantly higher in the vehicle-treated UNx db/db vs the vehicle-treated UNx db/m (Fig. 1D, p = 0.02), a typical feature of incipient DN. All treatments significantly decreased systolic and diastolic BP as compared to vehicle-treated UNx db/db due to its ramipril component (Fig. 1E). Further, both empagliflozin and semaglutide (alone or combined) on top of ramipril lowered blood glucose in UNx db/db (Fig. 1C, p<0.001 vs vehicle UNx db/db in all cases) but semaglutide component maximized this effect. Food and water intake was decreased in UNx db/db treated with semaglutide on top of RAS blockade (alone or combined with empagliflozin) as compared to vehicle-treated UNx db/db (Fig. 1B) although no differences in body weight were noted between treated and untreated UNx db/db (Fig. 1A). A trend towards ΔGFR decline was observed in UNx db/db treated with empagliflozin and semaglutide on top of RAS blockade (Fig. 1D). Finally, heart weight but not kidney weight was significantly lower in all treated UNx db/db as compared to vehicle-treated UNx db/db (Fig. 1F). Conclusion Our preliminary results show that addition of semaglutide to empagliflozin therapy on top of RAS blockade could have synergic hypoglycemic effects. Further, although more research is needed, both empagliflozin and semaglutide in combination with ramipril trended to ameliorate diabetic hyperfiltration and decreased heart weight in a DN mouse model which suggests cardiorenal beneficial effects.

Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice.

The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice

Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice

Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease

Empagliflozin Ameliorates Type 2 Diabetes Mellitus-Related Diabetic Nephropathy Via Altering the Gut Microbiota

Dapagliflozin attenuates renal fibrosis by suppressing angiotensin II/TGFβ signaling in diabetic mice

Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in prediabetic mice

Empagliflozin Regulates the AdipoR1/p-AMPK/p-ACC Pathway to Alleviate Lipid Deposition in Diabetic Nephropathy

Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK)

The Molecular Effects of SGLT2i Empagliflozin on the Autophagy Pathway in Diabetes Mellitus Type 2 and Its Complications

Assessing Early Tubular Protective Effects of SGLT2 Inhibitor Empagliflozin Against Type 2 Diabetes Mellitus Using Functional Magnetic Resonance Imaging.

Dmso_a_289712 227..240

Dapagliflozin Alleviates Renal Inflammation and Protects Against Diabetic Kidney Diseases, Both Dependent and Independent of Blood Glucose Levels

#4581 EVALUATION OF THE BENEFICIAL EFFECTS OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONIST ON TOP OF RAS BLOCKADE IN EXPERIMENTAL DIABETIC NEPHROPATHY

Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

Dapagliflozin Ameliorates Diabetic Kidney Disease via Upregulating Crry and Alleviating Complement Over-activation in db/db Mice

Differential Effects of Empagliflozin on Microvascular Complications in Murine Models of Type 1 and Type 2 Diabetes

385-P: MDSC-Mediated Neutrophil Extracellular Traps–Based Targeting of Diabetic Vasculopathy—Dapagliflozin for Vascular Remodeling in Diabetic Nephropathy

Investigating the impact of empagliflozin on the retina of diabetic mice